Status:
COMPLETED
A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia
Lead Sponsor:
Novartis
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
19+ years
Phase:
PHASE3
Brief Summary
This study is not being conducted in the United States. Key long-term clinical studies have shown that people with type 2 diabetes should try to achieve overall blood glucose levels as close to normal...
Eligibility Criteria
Inclusion
- Completion of study CLAF237A2307 within 4 weeks of entering into the extension
- Written informed consent
- Ability to comply with all study requirements
- Blood glucose criteria must be met
Exclusion
- Premature discontinuation from study CLAF237A2307
Key Trial Info
Start Date :
February 20 2006
Trial Type :
INTERVENTIONAL
End Date :
June 26 2007
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00300287
Start Date
February 20 2006
End Date
June 26 2007
Last Update
August 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Sites, Germany